-transparent.png){kind=logo}
Previously we reported that viramidine is a prodrug of ribavirin and that adenosine deaminase catalyses viramidine deamination to ribavirin in vivo. This in vivo study explores this prodrug conversion in rats and inhibition by a potent adenosine deaminase inhibitor, 2'-deoxycoformycin. We found that conversion of viramidine to ribavirin was viramidine dose-dependent in rat plasma. A single intravenous dose of 0.25 mg/kg 2'-deoxycoformycin suppressed orally administered viramidine conversion to ribavirin in plasma by 50%. The inhibition was 2'-deoxycoformycin dose-dependent and a single dose of 2 mg/kg decreased the ribavirin/viramidine area under the concentration-time curve between 0 h and 6 h ratio by 2.5-fold. These findings provide strong evidence that adenosine deaminase plays a major role in converting viramidine to ribavirin in vivo.
Jim Zhen Wu, and
Li-Tain Yeh, and
Chin-Chung Lin, and
Zhi Hong
February 1980,
Biochemical pharmacology,
Jim Zhen Wu, and
Li-Tain Yeh, and
Chin-Chung Lin, and
Zhi Hong
January 1984,
Advances in experimental medicine and biology,
Jim Zhen Wu, and
Li-Tain Yeh, and
Chin-Chung Lin, and
Zhi Hong
October 2003,
The Journal of antimicrobial chemotherapy,
Jim Zhen Wu, and
Li-Tain Yeh, and
Chin-Chung Lin, and
Zhi Hong
June 1978,
Journal of neurochemistry,
Jim Zhen Wu, and
Li-Tain Yeh, and
Chin-Chung Lin, and
Zhi Hong
October 1981,
Clinical immunology and immunopathology,
Jim Zhen Wu, and
Li-Tain Yeh, and
Chin-Chung Lin, and
Zhi Hong
November 1979,
Biochemical and biophysical research communications,
Jim Zhen Wu, and
Li-Tain Yeh, and
Chin-Chung Lin, and
Zhi Hong
January 1996,
Journal of medicinal chemistry,
Jim Zhen Wu, and
Li-Tain Yeh, and
Chin-Chung Lin, and
Zhi Hong
April 1979,
Cancer research,
Jim Zhen Wu, and
Li-Tain Yeh, and
Chin-Chung Lin, and
Zhi Hong
June 1992,
Clinical and experimental immunology,
Jim Zhen Wu, and
Li-Tain Yeh, and
Chin-Chung Lin, and
Zhi Hong
August 1979,
Cancer research,
